Global DNA Methylation Sequencing Market - 2021-2028

Global DNA Methylation Sequencing Market - 2021-2028

Market Overview

The global DNA methylation sequencing market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX% during the forecast period (2021-2028).

DNA methylation is a heritable epigenetic marker that involves DNA methyltransferases covalently transferring a methyl group to the C-5 position of the cytosine ring of DNA (DNMTs). In humans, cytosines are primarily methylated in any context of the genome. More than 98 percent of DNA methylation occurs in somatic cells in a CpG dinucleotide context.

Market Dynamics

The existing DNA methylation market is favored by several factors, including a global increase in cancer prevalence, declining sequencing costs, and increasing sequencing output. Furthermore, an increasing number of product approvals and launches in the global DNA methylation market will provide a lucrative growth opportunity for this market. Furthermore, the market is being driven by an increase in early-stage biomarkers in cancer profiling.

Increase in prevalance of cancer in the market will drive the market growth

Oncology is one of the disciplines where DNA methylation technology is widely employed to develop therapeutic options for rectifying the cancer epigenome's transcriptional aberrations. Changes in gene function or expression and cellular transformation lead to cancer when epigenetic alterations, such as DNA methylation and histone modification, are disrupted. The importance of DNA methylation technology in oncology may be seen in developing inhibitors of DNA methyltransferases and histone deacetylases (HDACs), which have been proven to be clinically effective in cancer treatment. According to the World Health Organization, approximately 1.8 million new cancer cases were diagnosed worldwide in 2018. According to the WHO, nearly 70% of cancer deaths occur in low- and middle-income countries. Only one in five low- and middle-income countries has the data needed to drive cancer-related policies. This global and widespread threat of cancer remains a major motivator for developing new cancer therapies that aid in risk assessment, early diagnosis, and effective treatment monitoring.

Government funding is also one of the main growth factors for the DNA methylation market. Increased government funding will help research institutes and key players develop and market novel assays useful for diagnosing various tumors. As funding increases, the cancer profiling market will become more liquid, and companies will develop new testing methods to identify the underlying mutations that may cause the disease. As a result, all of these factors are expected to contribute to market growth during the forecast period.This contributes to the growth of the global DNA methylation sequencing market.

High cost of instrument is likely to hamper the market growth

In developing economies, research and development spending primarily rely on funding from outside sources. Although governments and private bodies try to fund research programs, many research firms and academic institutes face budget constraints. They cannot afford advanced and high-priced equipment and technologies, which harms the growth of these industries and their expansion in developing countries. Furthermore, there is a scarcity of skilled professionals in this industry, further impeding its growth. As a result, interpreting complex data takes time, and researchers face challenges, resulting in slow industry growth.

COVID-19 Impact Analysis

Covid-19 has had an important impact on the industry's growth, economy, health, and mental well-being. In this difficult situation, every industry strives to provide the highest quality and safest services possible. The Covid –19 epidemic has harmed the DNA methylation industry's growth. Government regulations have hampered the movement of people and goods around the country. Due to the shutdown, the manufacturing process, supply chain, and import and export of goods and services suffered .Furthermore, people with hereditary abnormalities or long-term ailments were put on wait while the virus-infected population was given priority. On the other hand, researchers have developed the application and use of PCR and other genetic testing technologies in determining the nature of coronavirus and treatment options. Because of its use in virus diagnosis, PCR has become extremely important during pandemics. This fueled the market's expansion and increased demand for DNA methylation worldwide.

Segment Analysis

The polymerase chain reaction segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Polymerase Chain Reaction (PCR) and microarray are two DNA methylation techniques. Due to an increase in its application in diagnostics and DNA sequencing processes, the PCR segment held the largest market share in 2020. The expansion of DNA methylation was sparked by an increase in demand for PCR technology in diagnostics and genomics. PCR technique gained tremendous importance as a diagnostic method during Covid-19.

After bisulfite treatment, PCR-based approaches are commonly employed to investigate DNA methylation on a gene-by-gene basis. Bisulfite sequencing, methylation-specific PCR, real-time PCR-based MethyLight, and methylation-sensitive high-resolution melting PCR are variations of this approach. Several whole-epigenome profiling technologies, such as MethylC-seq reduced representation bisulfite sequencing (RRBS) and the Infinium Human methylation 450 K bead chip, are now available, allowing for the discovery of epigenetic drivers of disease processes as well as biomarkers that could be used in clinical practice.These factors are driving the growth of this segment.

Geographical Analysis

North America region holds the largest market share of global DNA methylation sequencing market

Due to the majority of companies in this region, North America accounted for the biggest market share in 2020. Furthermore, the region's vast network of manufacturing and R&D facilities and a surge in product launch and approvals and demand for protein expression systems all contribute to the growth of the DNA methylation market. The rise of the DNA methylation sector is fueled by the increased production of vaccines, antibodies, insulin, and hormones in this region. Furthermore, the United States is widely regarded as the world's top spender on healthcare facilities and research. During the projected period, the reasons mentioned above will contribute to the growth of the DNA methylation market.

The Asia Pacific area has the second-largest market share. Aside from technology developments, the DNA methylation sequencing service category is predicted to increase at a phenomenal rate over the study's forecast period. In addition to the areas mentioned above, Europe and South America held a significant market share in the worldwide DNA methylation market throughout the study period.

Competitive Landscape

The DNA methylation sequencing market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abcam plc,Active Motif Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc,Diagenode Diagnostics SA, EpiGentek Group Inc,Exact Sciences Corporation, F.Hoffmann-La Roche Ltd,Illumina Inc, Merck KGaA, New England Biolabs Inc, Pacific Biosciences of California Inc, Perkin Elmer Inc, QIAGEN N.V., Thermo Fisher Scientific Inc, Zymo Research Research Corporation.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the DNA methylation sequencing market globally. For instance,

In April 2019, New England Biolabs has released a new product called 'NEBNext Enzymatic Methyl-seq (EM-seqTM)' as a methylation analysis alternative to bisulfite sequencing.

In Jan 2018, Thermo Fisher Scientific and Illumina have announced an official agreement to market AmpliSeq technology to researchers for scientific projects.

In November 2019, PerkinElmer, Inc. has released a new product called ""NEXTFLEX® ChIP-Seq Kit."" The newly released product is used to precisely scan interactions between protein, DNA, and RNA, allowing for interpreting regulatory events that are important in many biological processes and disease states.

Illumina Inc

Overview: Illumina, Inc. offers sequencing and array-based genetic and genomic analysis products. Its goods and services enable the adoption of genomic solutions in research and clinical settings for applications in the oncology, life sciences, reproductive health, agriculture, and other growing segments through its products and services. The company offers genotyping and sequencing services, instrument service contracts, development and licensing agreements, and devices and consumables for genetic analysis. Pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics enterprises are among its customers, as are genomic research institutes, academic institutions, government laboratories, and hospitals.

Product Portfolio:

TruSeq Methyl Capture EPIC Library Prep : Targeted methylation sequencing (Methyl-Seq) provides a cost-effective, balanced alternative to whole-genome bisulfite sequencing and methylation arrays for screening and biomarker discovery studies. TruSeq Methyl Capture EPIC Library Prep aids researchers who want to learn more about how methylation affects gene regulation.

Why Purchase the Report?

Visualize the composition of the global DNA methylation sequencing market segmentation by technology, product, application, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global DNA methylation sequencing market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global DNA methylation sequencing market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global DNA methylation sequencing market report would provide an access to an approximately 40+ market data table, 45+ figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global DNA Methylation Sequencing Market- By Product

Instruments

Consumables

Software

Global DNA Methylation Sequencing Market– By Technology

Polymerase chain reaction

Microarray

Others

Global DNA Methylation Sequencing Market- By Application

Oncology Research

Non-Oncology Research

Clinical Application

Translational Research

Global DNA Methylation Sequencing Market– By End User

Pharmaceutical and Biotechnology Companies

Research Centers

Contract Research Organizations

Others

Global DNA Methylation Sequencing Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America